Molecular targeting therapy for pancreatic cancer: current knowledge and perspectives from bench to bedside

被引：38
作者：
Furukawa, Toru [1 ]
机构：
[1] Tokyo Womens Med Univ, Int Res & Educ Inst Integrated Med Sci, Shinjuku Ku, Tokyo 1628666, Japan
来源：
JOURNAL OF GASTROENTEROLOGY | 2008年 / 43卷 / 12期
关键词：
pancreatic cancer; molecular targeting; RAS-MAPK; PI3K-AKT; hedgehog;
D O I：
10.1007/s00535-008-2226-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Current medical interventions for pancreatic cancer are insufficient. Recent molecular investigations have elucidated complex genetic mechanisms of cancer that especially involve multiple signal transduction pathways; this enables us to develop molecular medicines targeting specific genetic molecules in the pathways. These molecular medicines seem to promise clues for curing cancers, including pancreatic cancer. This review describes current knowledge and perspectives regarding the development of molecular medicines for pancreatic cancer by focusing on growth factor receptor systems and three major signal transduction pathways: the RAS-MAPK, PI3K-AKT-mTOR, and hedgehog pathways.
引用
收藏
页码：905 / 911
页数：7
相关论文
共 63 条
[31]   Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer [J].
Kindler, HL ;
Friberg, G ;
Singh, DA ;
Locker, G ;
Nattam, S ;
Kozloff, M ;
Taber, DA ;
Karrison, T ;
Dachman, A ;
Stadler, WM ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8033-8040
[32]   Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions [J].
Kolch, W .
BIOCHEMICAL JOURNAL, 2000, 351 :289-305
[33]   Targeted inhibition of hedgehog signaling by cyclopamine prodrugs for advanced prostate cancer [J].
Kumar, Srinivas K. ;
Roy, Indrajit ;
Anchoori, Ravi K. ;
Fazli, Sarah ;
Maitra, Anirban ;
Beachy, Philip A. ;
Khan, Saeed R. .
BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (06) :2764-2768
[34]   Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplilications, and KRAS mutations on survival of pancreatic adenocarcinoma [J].
Lee, Jeeyun ;
Jang, Kee-Taek ;
Ki, Chang-Seok ;
Lim, Taekyu ;
Park, Young Suk ;
Lim, Ho Yeong ;
Choi, Dong-Wook ;
Kaing, Won Ki ;
Park, Keunchil ;
Park, Joon Oh .
CANCER, 2007, 109 (08) :1561-1569
[35]   Dose- and route-dependent teratogenicity, toxicity, and pharmacokinetic profiles of the Hedgehog signaling antagonist cyclopamine in the mouse [J].
Lipinski, Robert J. ;
Hutson, Paul R. ;
Hannam, Paul W. ;
Nydza, Robert J. ;
Washington, Ida M. ;
Moore, Robert W. ;
Girdaukas, Gary G. ;
Peterson, Richard E. ;
Bushman, Wade .
TOXICOLOGICAL SCIENCES, 2008, 104 (01) :189-197
[36]   Antiangiogenic therapy with mammalian target of rapamycin inhibitor RAD001 (Everolimus) increases radiosensitivity in solid cancer [J].
Manegold, Philipp C. ;
Paringer, Carmen ;
Kulka, Ulrike ;
Krimmel, Klaus ;
Eichhorn, Martin E. ;
Wilkowski, Ralf ;
Jauch, Karl-Walter ;
Guba, Markus ;
Bruns, Christiane J. .
CLINICAL CANCER RESEARCH, 2008, 14 (03) :892-900
[37]   Cancer incidence and incidence rates in Japan in 2000: Estimates based on data from 11 population-based cancer registries [J].
Marugame, Tomomi ;
Kamo, Ken-Ichi ;
Katanoda, Kota ;
Ajiki, Wakiko ;
Sobue, Tomotaka .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2006, 36 (10) :668-675
[38]   Pancreatic Cancer Registry in Japan - 20 years of experience [J].
Matsuno, S ;
Egawa, S ;
Fukuyama, S ;
Motoi, F ;
Sunamura, M ;
Isaji, S ;
Imaizumi, T ;
Okada, S ;
Kato, H ;
Suda, K ;
Nakao, A ;
Hiraoka, T ;
Hosotani, R ;
Takeda, K .
PANCREAS, 2004, 28 (03) :219-230
[39]   Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies [J].
Mita, Monica M. ;
Mita, Alain C. ;
Chu, Quincy S. ;
Rowinsky, Eric K. ;
Fetterly, Gerald J. ;
Goldston, Michelle ;
Patnaik, Amita ;
Mathews, Lesley ;
Ricart, Alejandro D. ;
Mays, Theresa ;
Knowles, Heather ;
Rivera, Victor M. ;
Kreisberg, Jeff ;
Bedrosian, Camille L. ;
Tolcher, Anthony W. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (03) :361-367
[40]   Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group [J].
Moore, Malcolm J. ;
Goldstein, David ;
Hamm, John ;
Figer, Arie ;
Hecht, Joel R. ;
Gallinger, Steven ;
Au, Heather J. ;
Murawa, Pawel ;
Walde, David ;
Wolff, Robert A. ;
Campos, Daniel ;
Lim, Robert ;
Ding, Keyue ;
Clark, Gary ;
Voskoglou-Nomikos, Theodora ;
Ptasynski, Mieke ;
Parulekar, Wendy .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (15) :1960-1966
1234567